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Abstract
Chitosan was recently indicated to enhance osteogenesis, improve wound healing but to activate the coagulation and the
complement systems. In the present study approximately 10 nm thick chitosan ﬁlm were prepared on aminopropyltriethoxysilane
(APTES) coated silicon. The surfaces were incubated in serum or plasma and subsequently in antibodies towards key complement
and contact activation of coagulation proteins. The deposited amounts were compared with those on hydrophilic and hydrophobic
silicon, APTES and IgG coated reference samples. Although large amounts of serum deposited to chitosan only a weak transient
activation of the complement system and no activation of the intrinsic pathway was observed. Upon acetylation the chitosan layer
became a strong activator of the alternative pathway of the complement. After incubation in human plasma anti-ﬁbrinogen
deposited onto chitosan but not onto the acetylated chitosan, a ﬁnding that may explain previous observations of procoagulant
activity by chitosan. r 2002 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Chitosan is the deacetylated form of one of the most
abundant natural polymer, chitin or poly(b(1–4)
GlcNAc). It is shown to enhance osteogenesis [1] and
improve wound healing [2] and is used for biomaterials
applications such as artiﬁcial skin, wound dressings and
sutures [3]. However, it is indicated in the literature that
chitosan has the capacity to activate both complement
[4] and blood coagulation systems [5]. Surprisingly few,
if any, studies have until now been performed to more in
detail analyze the protein adsorption properties of
chitosan and its capacity to activate the humoral
systems in complex protein ﬂuids such as blood serum.
Hence, in the present study APTES coated surfaces were
layered with chitosan and subsequently incubated in
serum or plasma. Polyclonal antibodies towards a few
selected serum proteins were used to detect the binding
and activation of complement factors and the intrinsic
pathway of coagulation proteins. The adsorbed
amounts of chitosan, serum and antibodies were
quantiﬁed by single wavelength null ellipsometry [6].
The present results conﬁrm that chitosan activates the
complement cascade and that the activation depends on
the degree of acetylation.
2. Experimental
2.1. Surface preparations
Polished silicon wafers (Okmetic, Finland) were
hydrophilized by washing in deionized water (Milli-Q,
18.2MO cm) with 30% H2O2 and 25% NH4OH in 5:1:1
proportions for 5–10min at 801C, rinsed in Milli-Q
water with 30% H2O2, 37% HCl in 6:1:1 proportions
for 5–10min at 801C, and ﬁnally rinsed in Milli-Q water.
The clean hydrophilic pieces were hydrophobized by the
following procedure: the threefold rinsing in 99.5%
ethanol and three rinsings in xylene was followed by a
5min incubation in 1%v/v dichlorodimethylsilane in
xylene and ﬁnally rinsed three times in xylene and in
ethanol, respectively. The samples were stored in 99.5%
ethanol until use. Some hydrophilic silicon pieces were
rinsed in ethanol and acetone and incubated in 1%
aminopropyltriethoxysilane (APTES) for 10min at
room conditions followed by rinsings in acetone and
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ethanol. These samples were used immediately. Most of
the APTES coated pieces were incubated in a mixture of
high molecular weight chitosan (600 kDa, 85% deace-
tylated, Fluka), NaCl and glutardialdehyde dissolved in
0.1m acetic acid (HAc) supplemented with 0.25mm
sodium azide. Different pH (adjusted with sodium
hydroxide), sodium chloride concentrations and incuba-
tion times were used to test the binding of chitosan. The
remaining aldehydes were terminated by incubations for
at least 4 h in 1m ethanolamine adjusted to pH 5 with
HAc. One set of chitosan layers was also N-acetylated
through incubation in 200mm 1-ethyl-3-(3-diaminopro-
pyl)carbodiimide (EDC) and 50mm N-hydroxysuccini-
mide (NHS) in 0.1m HAc at pH 5 over night.
Loose aggregates of glutardialdehyde crosslinked
chitosan formed during the chitosan immobilization
procedure were rinsed with HAc and water and
incubated in ethanolamine, rinsed and incubated in
NHS/EDC/HAc as above. The aggregates were freezing
dried, grounded with KBr and made into pellets for the
FTIR (Bruker IFS 48) chemical analysis.
As a positive complement activation control hydro-
phobic samples were adsorption coated with normal
human IgG (1mg/ml, 30min, Gammaglobulin, Phar-
macia & UpJohn, Sweden). The hydrophilic Si samples
were used as positive controls for contact activation of
coagulation and the hydrophobic Si as negative controls
(relatively low-activator of both the complement and
coagulation systems).
2.2. Serum, plasma and antibody incubations
Veronal buffer (VB) was prepared from 3mm 5,50-
dietylbarbituric acid, 2mm of it’s corresponding sodium
salt and 145mm NaCl. VB2+ buffer was prepared
through the addition of 0.5mm MgCl2 and 0.15mm
CaCl2 to VB. EGTA-serum was prepared by addition
of 2.5mm MgCl2 and 10mm ethylene glycol-bis(beta-
aminoethylether)-N,N,N0,N0-tetraacetic acid (EGTA) to
serum that was diluted with VB buffer. Both the VB and
VB2+ buffers were prepared from deionized and ﬁltered
water (Milli-Q, 18.2MO cm), adjusted to pH 7.4 and
supplemented with 0.25mm sodium azide.
The above modiﬁed surfaces were incubated in 67%
normal human serum (pooled from two apparently
healthy individuals) in VB2+ or VB/EGTA buffer for 5
or 60min at 371C. After each incubation the samples
were extensively rinsed in respective buffer and trans-
ferred to polyclonal antibody solutions (diluted 1:50 in
VB2+) and incubated for 30min at 221C. The antibodies
were directed towards the following human antigens:
immunoglobulin G (IgG), complement factors 1q, 3c
and 3d (C1q, C3c and C3d) and human serum albumin
(HSA) (Dako, Denmark), and properdin (prop), high
molecular weight kininogen (HMWK), and coagulation
factor XII (FXII) and prekallikrein (PKK) (Nordic
Immunology, the Netherlands).
Similar experiments were performed with 5min
incubations of the surfaces in 67% heparinized plasma
in VB2+ at 371C, followed by incubation in solutions of
polyclonal antibodies towards ﬁbrinogen and von Will-
ebrand Factor (vWF) (Dako, Denmark). All samples
were rinsed in respective buffer before and after each
incubation.
2.3. Null ellipsometry
The samples were rinsed with deionized water, blown
dry with nitrogen and measured at three locations in air
with a Rudolph Research AutoEL III bench null
ellipsometer at 632.8 nm at 701 angle of incidence and
one zone. The thicknesses of the adsorbed ﬁlms were
calculated using the built-in software assuming a ﬁlm
refractive index Nfilm ¼ 1:5 and a silicon substrate
refractive index Nsubstrate¼ 3:85820:018i: The surface
protein concentration, G (mg/cm2), was calculated
according to the one component model for air measure-
ments using M=A=4.14 where M=molar mass (g/mol)
and A=molar refractivity (cm3/mol) as outlined by
Cuypers [7].
2.4. Atomic force microscopy (AFM)
A NanoScope IIIa (Digital Instruments, USA) AFM
was run in the tapping modeTM. The surface roughness
(Sq) before and after chitosan depositions were calcu-
lated with the built-in instrument software on images
with 5 mm scan size after a third degree plane ﬁt.
2.5. Statistical evaluation
The adsorbed amounts of chitosan, serum and
antibodies were tested using the Student’s t-test against
the null hypothesis of no adsorption. Adsorbed amounts
signiﬁcantly (a ¼ 0:05) above zero are marked with an
asterisk (*) in the graphs. The average depositions and
standard errors of means are displayed in the graphs.
The chitosan immobilization experiments were per-
formed in triplicate, the serum and antibody experi-
ments 6 times and the plasma and antibody experiments
4 times.
3. Results and discussion
3.1. Chitosan films on silicon
Because of the large extent of hydrogen bonding in
saccharide polymers their FTIR spectra become difﬁcult
to interpret. In our study, the interpretation was focused
on the differences between the differently treated
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chitosan samples in the spectral range 1800–1300/cm
(Fig. 1). The amide I (approx. 1650/cm) and amide II
(approx. 1560/cm) peaks were present in all samples
although at different proportions and at peak positions
depending on the chemical treatments. The peak at
1710–1720/cm probably originates from aldehyde
groups after the glutardialdehyde treatment. This peak
disappeared after ethanolamine incubation, as expected
if the aldehydes react with amines. The peak reappeared
after an NHS/EDC/HAc incubation since a similar
vibration can also be found in ketones. The decrease of
the 1596/cm peak after glutardialdehyde incubations
may be due to a decreased amount of primary amines.
The increase of the 1380/cm peak after an NHS/EDC/
HAc incubation may be due to an increase in the acetyl
methyl content. The relative increase of the amide I
compared to amide II band after incubation in EDC/
NHS/HAc also supports the hypothesis of an increased
acetylation, since the amide I band (C=O stretch) is
normally stronger than the amide II band.
The amount of APTES bound chitosan increased with
increasing NaCl concentration, pH and time (Figs. 2A
and B). The results are in accordance with previous
studies on the gelation of the chitosan–glutardialdehyde
system that demonstrated a decrease in the gelation time
with increasing NaCl, chitosan and glutardialdehyde
concentrations [8,9]. After 60min of incubation in
0.4mg/ml chitosan, 1% glutardialdehyde and 1m NaCl
approximately 10 nm thick layers of chitosan remained
ﬁrmly bound to the APTES surfaces (Fig. 2B). The
chitosan was successfully immobilized at pH 4.5 and 5
but not at pH 3 and 4 (Fig. 2A). The coupling to APTES
surfaces took several hours to complete although most
of the deposition occurred within the ﬁrst hour
(Fig. 2B). This is in contrast to a recent study that
indicated a chitosan glutardialdehyde crosslinking in
less than an hour for completion at pH 3 and 4 [10]. A
further increase in the chitosan and glutardialdehyde
concentrations or a prolonged incubation time increased
the deposition although the layer became then unevenly
distributed. In extreme cases the average ellipsometric
thickness was in the range between 20 nm to several
hundreds of nm at different spots on the same sample.
Since the chitosan layers were to be studied with serum
and antibody solutions they needed to be even with an
acceptable thickness variation of approximately 1 nm.
Hence most of the prepared chitosan ﬁlms were
prepared to about 10 nm thickness and with thickness
variation of less than 10%.
The stability of the covalent binding between chitosan
and the glutardialdehyde activated APTES coated
surface was tested by sonication of the chitosan coated
surfaces in 0.1m HAc for 10min. No signiﬁcant (less
than 5%) loss of material was observed.
Fig. 1. FTIR spectra of chitosan before and after acetylation. Most
vibrational information regarding the effects of the chemical treat-
ments was in this study found in the wave number range 1800–1300/
cm. The inset is the full spectra from 4000 to 1000/cm.
Fig. 2. (A) The average chitosan layer thickness on APTES surfaces at
varying pH (adjusted with NaOH) and NaCl concentrations. The
surfaces were incubated for 60min in 0.4mg/ml chitosan and 1wt%
glutardialdehyde dissolved in 0.1m HAc. (B) The average chitosan
layer thickness at increasing NaCl concentrations and incubation
times. The surfaces were incubated in 0.4mg/ml chitosan and 1wt%
glutardialdehyde dissolved in 0.1m HAc that was adjusted to pH 5
with NaOH.
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Alternating incubations of APTES coated samples in
either chitosan or glutardialdehyde in 0.1m HAc
resulted in less than 0.5 nm thickness additions per cycle
to the APTES surfaces irrespective of the incubation
time, pH or NaCl concentration. Attempts were also
made to cover the Si samples with chitosan by
incubations in dilute chitosan solutions (1 mg/ml–1mg/
ml) in 0.1m HAc followed by evaporation of the solvent,
although such coatings became very rough and not
appropriate for our purposes.
It is a drawback in bio-applications to use the
cytotoxic glutardialdehyde [11] for immobilization
purposes. However, the termination of the remaining
aldehydes with ethanolamine is feasible and minimizes
the problems with the reactive residues during tissue
contact, in case such surfaces were implanted.
The ellipsometric thickness determination is an
average over the ca. 0.6mm2 laser spot area, and hence
the more detailed topography of the chitosan layers was
determined by AFM. The data indicated a fairly high
surface roughness, Sq=5 nm, compared to the average
layer thickness of 10 nm. In comparison, the APTES
coated surfaces had a surface roughness of Sq=0.5 nm.
However, as the surfaces were completely coated with
chitosan and as null ellipsometry is an averaging method
for the determination of ﬁlm thicknesses the surface
roughness was no problem during the protein deposition
measurements.
3.2. Serum and antibody depositions
The serum and antibody depositions in Figs. 3A–E
show the positive and negative complement and contact
activation controls for the investigated chitosan coated
surfaces shown in Figs. 4A–C.
3.2.1. Complement
Hydrophobic silicon is a low activator of both the
complement and coagulation cascade systems (Fig. 3A).
After serum incubation none of the intrinsic pathway of
coagulation proteins were antibody detectable and only
small amounts of anti-C3c was deposited. Notably,
HSA was antibody detectable on hydrophobic silicon,
indicating a low activation and hence additional protein
deposition of the humoral systems. On activator
surfaces on the other hand, the formed protein
complexes often cover and thereby sterically hinder
antibody detection of a previously adsorbed HSA.
One example of a strong classical pathway comple-
ment activator surface is IgG coated hydrophobic
silicon [12] (Fig. 3B). Note especially both the high
serum and high anti-C3c deposition already after 5min
serum incubation. Through the chelation of Ca2+ with
EGTA the classical pathway can be inhibited [13,14] and
the time delayed alternative pathway activation [12,15]
can be observed (Fig. 3C). The time delay of activation
was indicated also by the detection of C1q to IgG after
5min of EGTA-serum incubation but not otherwise.
After the EGTA-serum incubation both the deposited
amounts of serum and anti-C3c were low after 5min and
high after 60min (Fig. 3C) [12,16]. This also explains the
high anti-HSA binding on IgG coated surfaces after
5min of EGTA-serum incubation and low after 60min
(Fig. 3C).
Observe also that the increase in the deposition of
anti-properdin indicates the presence of surface bound,
functional and stabilized C3-convertases [17] of the
alternative pathway [12] (see e.g. Fig. 3B). Furthermore,
a low serum, anti-C3c and anti-properdin deposition
after 5min serum incubation but high of these three
after 60min of incubation strongly indicate an alter-
native pathway of complement activation (Fig. 3C). On
surfaces that activate complement and where the
inhibition of complement occurs also the presence of
C3d, a degradation product of C3b is expected. C3b is
suggested to possess the ability to bind covalently to
surface nucleophiles [18,19] such as the amine termi-
nated APTES that is a weak alternative pathway
activator [20] (Fig. 3D) as can be seen from the low
depositions of serum and antibodies compared to that
on the IgG coated surfaces after EGTA serum incuba-
tions (Fig. 3C).
Relatively large amounts of serum proteins adsorbed
to chitosan after 5min of incubation (Fig. 4A and B)
and this is often indicative of a complement activator
surface [6,12,16], cf. Fig. 3D. However, only small
amounts of anti-C3c bound to the serum incubated
chitosan ﬁlm and the anti-properdin deposition was
negligible, indicating no or a rapidly inhibited comple-
ment activation in spite of a low but still detectable, and
previously not observed deposition of anti-IgG. In
contrast, no anti-IgG deposition was observed onto
the APTES coated surfaces after serum incubations
(Fig. 3D).
When the chitosan layer was charge neutralized
through the addition of acetyl groups to amines the
ﬁlms became strong activators of the alternative path-
way of complement (Fig. 4CFcf. Fig. 3B). This sug-
gests a strong electrostatic interaction between the more
positively charged (deacetylated) chitosan and many
blood proteins carrying a net negative charge at pH 7.4.
Tentatively such proteins block or inhibit the activation
of complement. Recent studies show that the degree of
chitosan deacetylation is important for its complement
activation properties in vivo and in vitro [4,21]. One of
the studies performed in dogs indicated that chitin and
chitosan activate the alternative pathway of complement
as effectively as zymosan [4], a well known alternative
pathway of complement activator. It was also shown
in vitro that the activation of macrophages depended on
the degree of deacetylation and substitution of chitosan
[22] and that GlcNAc was more efﬁcient for macro-
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Fig. 3. (A) Normal serum (5 and 60min incubation times) and subsequent net antibody depositions to hydrophobic silicon. This is a negative control
for the activation of the intrinsic pathway of coagulation and a weak complement activator. Signiﬁcant (po0:05) depositions are marked with an
asterisk (*). (B) Normal serum and subsequent net antibody depositions to IgG coated hydrophobic silicon. The surface is a strong classical
complement pathway activator and a negative control for contact activation of coagulation. (C) EGTA-serum and subsequent net antibody
depositions to IgG coated hydrophobic silicon. The system shows a typical alternative pathway complement activation and is a negative control for
contact activation of coagulation. (D) Normal serum and subsequent net antibody depositions to APTES coated silicon surfaces. The surface is a
positive control for a relatively weak alternative complement pathway activation by amine containing surfaces, and a negative control for contact
activation of coagulation. (E) Normal serum and subsequent net antibody depositions to hydrophilic silicon. This surface is a positive control for
contact activation of coagulation and a weak complement activator. Observe the relatively high binding of anti-HMWK after the serum incubations.
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phage activation than GlcN in vivo and in vitro [23].
Since macrophages express complement receptors and
become activated by complement [24], these ﬁndings
support the present results where chitosan (Fig. 4A–B)
(containing mostly GlcN) did not the activate comple-
ment system whereas the acetylated form (containing
more GlcNAc) was a strong alternative pathway of
complement activator (Fig. 4C).
3.2.2. Contact activation
Negatively charged surfaces that activate the intrinsic
pathway of coagulation (contact activation) bind
relatively large amounts of anti-HMWK after serum
(or plasma) incubations, as observed on hydrophilic
silicon (Fig. 3E) but not on the hydrophobic Si or the
IgG coated samples (Fig. 3A–C). As expected, only
small amounts of anti-HMWK deposited onto the
positively charged APTES surfaces (Fig. 3D). On
activator surface also anti-FXII and anti-PKK deposit
but these were not detectable in this study, perhaps due
to the use of serum instead of plasma or whole blood in
our in vitro experiments. The anti-HMWK binding
contradicts a previous study where HMWK did not
adsorb to negatively charged surfaces after incubation in
FXII deﬁcient plasma and where also the HMWK
adsorption was lowered in PKK deﬁcient plasma [25].
Thus, the low the deposition of anti-HMWK in the
present study onto the three types of chitosan coatings is
therefore surprising (Fig. 4A–C). Since all three contact
activation proteins (HMWK, PKK and FXII) were
concurrently not antibody detectable, chitosan did
apparently not activate the intrinsic pathway of
coagulation. The results are more in line with other
studies indicating that chitosan triggers coagulation
without the activation of the intrinsic pathway [5,26,27].
Maybe the deposition of ﬁbrinogen from plasma and
concomitant binding of platelets accounts for this
activation, see Section 3.3. The activation was, however,
Fig. 4. (A) Normal serum (5 and 60min incubation times) and subsequent net antibody depositions to chitosan that was immobilized to APTES
coated surfaces by glutardialdehyde. Signiﬁcant (po0:05) protein depositions are marked with an asterisk (*). (B) Normal serum and subsequent net
antibody depositions onto chitosan that was coupled to APTES coated surfaces by glutardialdehyde. The residual aldehydes were terminated by an
overnight incubation 1m ethanolamine at pH 5. (C) Normal serum and subsequent net antibody deposition onto acetylated chitosan. This surface
was prepared from chitosan that was coupled to APTES coated surfaces by glutardialdehyde. The residual aldehydes were terminated by an over
night incubation 1m ethanolamine at pH 5. The residual amines were acetylated through overnight incubation in 200mm EDC, 50mm NHS and
100mm HAc at pH 5.
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slower than that observed on glass [28], the positive
control for intrinsic pathway activation. Another study
indicated that chitosan induced blood coagulation in
vitro was independent on FVII but required FXI and
FXII [29]. Also, it has been shown that coagulation
proceeds faster in whole blood when chitosan is
introduced and even minute amounts can agglutinate
red blood cells [26]. Chitosan was therefore proposed for
use as a hemostatic agent prior to that study [5,27].
3.2.3. Anti-HSA and anti-properdin vs. anti-C3c
deposition
Relatively large amounts of anti-HSA deposited to
the chitosan, hydrophobic Si and IgG (5min in EGTA
serum only) coated samples after serum incubations.
The latter two cases indicates that anti-HSA binds to
non-activating surfaces, thus implying that chitosan also
is a non- or low-activator. In order to further analyze
this aspect, the deposition of anti-HSA and anti-
properdin were plotted vs. anti-C3c deposition (Fig. 5)
for the studied surfaces.
Overall, a large anti-C3c deposition was paralleled of
large anti-properdin deposition (not shown) indicating
that alternative pathway of complement C3-convertases
become stabilized and increase in amount with time on
activator surfaces.
In contrast, anti-C3c deposition was high when anti-
HSA deposition was low, but when anti-C3c deposition
was low anti-HSA deposition was not necessarily high
(Fig. 5). One exception was the acetylated chitosan
where large amounts of anti-HSA deposited after 60min
of serum incubation even though it is a relatively strong
alternative pathway of complement activator with a
high anti-C3c deposition. This suggests that when both
anti-C3c and anti-HSA depositions were low other
proteins adsorbed and sterically hindered their detection
on the surfaces.
3.3. Plasma and antibody depositions
After 5min of incubation in heparin plasma ﬁbrino-
gen was antibody detectable on the positively charged
chitosan but not on acetylated chitosan (Fig. 6). This
may explain previous ﬁndings that chitosan activates the
coagulation of blood [5,26,27] by offering binding sites
to platelets that in turn trigger the primary hemostasis
by binding via GPIIb/IIIa to the adsorbed ﬁbrinogen
[30,31]. The degree of binding and activation depends,
however, on the conformation of the adsorbed ﬁbrino-
gen [32]. Also, the platelets need to become activated e.g.
by thrombin before the GPIIb/IIIa receptor is able to
bind to ﬁbrinogen [33], which may happen e.g. when the
alternative pathway of complement C3 convertases
cleave prothrombin to thrombin [34,35]. The second
important platelet activator protein, von Willebrand
Factor (vWF) was on the other hand not antibody
detectable on any of the surfaces under study.
4. Summary
Thin chitosan ﬁlms that were prepared by glutardial-
dehyde crosslinking of chitosan to APTES coated
samples appeared to be weak activators of the alter-
native pathway of complement and the intrinsic path-
way of coagulation. However, acetylation turned the
chitosan coating into a strong alternative pathway
activator. Large amounts of ﬁbrinogen and other
plasma proteins bound to chitosan but not to acetylated
chitosan, a fact that may explain the previously
observed procoagulant behavior of chitosan.
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